Striate+™ global exclusive license and manufacturing agreement with BioHorizons

27 June 2022
Posted in Company News
27 June 2022 Orthocell

Orthocell (ASX:OCC) has signed a global exclusive license and manufacturing agreement for its FDA-cleared dental product, Striate+™, with BioHorizons Implant Systems Inc – one of the largest dental implant companies in the world. 

Under the terms of the agreement, BioHorizons has agreed to pay AUD $23.1 million (USD $16 million) for an exclusive license of intellectual property relating to Striate+™. Orthocell will supply BioHorizons with Striate+™products, and grant BioHorizons exclusive distribution rights for these products globally. 

​​President and CEO of BioHorizons, Steve Boggan, said:

“We are very pleased to partner with Orthocell to offer our valued customers a dental membrane with excellent handling properties and regenerative potential.  Striate+™ will be a highly complementary addition to our global biomaterials product portfolio for dental tissue regeneration.”

BioHorizons is part of Henry Shein, Inc., a leading global provider of dental implants  and tissue regeneration products for dentists and dental specialists. Striate+™ will sit seamlessly amongst its portfolio of innovative dental implant and tissue regeneration products, designed to improve the lives of patients with missing teeth. 

Click here to read today’s ASX release.